LQT3: Who is at risk for sudden cardiac death?

Heart Rhythm

Volumn 6, Issue 1, 2009, Pages 121-122

  Eckardt, Lars ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; MEXILETINE;

CARDIOVASCULAR RISK; CARDIOVERSION; CLINICAL FEATURE; DEFIBRILLATION; ECHOCARDIOGRAPHY; EDITORIAL; GENOTYPE; HEART DEATH; HIGH RISK PATIENT; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; SUDDEN DEATH;

ADULT; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; DNA; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; FEMALE; GENOTYPE; HUMANS; INCIDENCE; LONG QT SYNDROME; MALE; MUSCLE PROTEINS; MUTATION; RISK FACTORS; SODIUM CHANNELS;

EID: 58049184021     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2008.12.004     Document Type: Editorial

References (21)

1. Jervell A., and Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval, and sudden death. Am Heart J 54 (1957) 59-68
2. Vincent G.M. Genotyping has a minor role in selecting therapy for congenital long-QT syndromes at present. Circ Arrhythm Electrophysiol 117 (2008) 227-233
3. Moss A.J., and Goldenberg I. Importance of knowing the genotype and the specific mutation when managing patients with long-QT syndrome. Circ Arrhythm Electrophysiol 117 (2008) 219-226
4. Zipes D.P., Camm A.J., Borggrefe M., et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines. Circulation 114 (2006) 385-484
5. Zareba W., Moss A.J., Schwartz P.J., et al. Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med 339 (1998) 960-965
6. Etheridge S.P., Sanatani S., Cohen M.I., et al. Long QT syndrome in children in the era of implantable defibrillators. J Am Coll Cardiol 50 (2007) 1335-1340
7. Schwartz P.J., Spazzolini C., and Crotti L. All LQT3 patients need an ICD. True or false?. Heart Rhythm 6 (2009) 113-120
8. Priori S.G., Napolitano C., Gasparini M., et al. Natural history of Brugada Syndrome: insights for risk stratification and management. Circulation 105 (2002) 1342-1347
9. Eckardt L., Probst V., Smits J.P., et al. Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation 111 (2005) 257-263
10. Goldenberg I., Moss A.J., Bradley J., et al. Long-QT syndrome after age 40. Circulation 117 (2008) 2192-2201
11. Goldenberg I., Moss A.J., Peterson D.R., et al. Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation 117 (2008) 2184-2191
12. Hobbs J.B., Peterson D.R., Moss A.J., et al. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA 296 (2006) 1249-1254
13. Sauer A.J., Moss A.J., McNitt S., et al. Long QT syndrome in adults. J Am Coll Cardiol 49 (2007) 329-337
14. Schwartz P.J., Priori S.G., Locati E.H., et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na(+) channel blockade and to increases in heart rate: implications for gene-specific therapy. Circulation 92 (1995) 3381-3386
15. Priori S.G., Napolitano C., Schwartz P.J., et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 292 (2004) 1341-1344
16. Ruan Y., Liu N., Bloise R., et al. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation 116 (2007) 1137-1144
17. Benhorin J., Taub R., Goldmit M., et al. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?. Circulation 101 (2000) 1698-1706
18. Windle J.R., Geletka R.C., Moss A.J., et al. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation. Ann Noninvas Electrocardiol 6 (2001) 153-158
19. Moss A.J., Zareba W., Schwarz K.Q., et al. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol 19 (2008) 1289-1293
20. 2+ exchanger suppresses torsades de pointes in an intact heart model of long QT syndrome-2 and long QT syndrome-3. Heart Rhythm 5 (2008) 1444-1452
21. Schwartz P.J. The idiopathic long QT syndrome: the need for a prospective registry. Eur Heart J 4 (1983) 529-531